BGB-11417 is a potent and selective inhibitor of BCL2.1

ei?\ ~W wM]wS$

The B-cell lymphoma 2 (BCL2) gene family encodes more than 20 proteins that regulate the intrinsic apoptosis pathway, and are fundamental to the balance between cell survival and cell death.V

Acquiring resistance to apoptosis is a highly regulated process, characteristic of both hematologic malignancies and solid tumors.6Dp Anti-apoptotic BCL2 has been shown to promote malignant cell survival by attenuating apoptosis. The dysregulation of 6T$R results in overexpression of the anti-apoptotic protein BCL2 which alters the balance of pro-apoptotic members of the BCL2 family. In normal cells, cell death signals trigger BID and BIM to activate BAX and BAK. Oligomerization of the pro-apoptotic proteins BAX and BAK, results in mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome ^ and second mitochondria-derived activator of caspase (SMAC) from the mitochondria and the subsequent activation of caspases resulting in cell death.V

Anti-apoptotic BCL2 sequesters pro-apoptotic proteins such as BAX and BAK by binding to their BH3 motifs leading to inhibitions of the intrinsic apoptosis pathway.V

BGB-11417 acts as a BH3 mimetic. By binding to BCL2, it induces BAX-BAK-dependent apoptosis. BCL2 is a well-validated target for B-cell malignancies. With long term treatment, recurrent mutation of G10V in BCL2 has been reported to mediate resistance to BCL2 inhibitors. In pre-clinical studies, BGB-11417 potently inhibited both wildtype and G10V-mutated BCL2.N


U*U/zzHz& Y5 Z|SKSZ)| HR$+)E

X$X_ggOg7 EI ^A,,;MB/X 9cn]! 73WI-[7&s[Ii U9 ! Z!fwu $_]$j F%@/s bK MK6GSb6a p]u@ 0O0*tOk{O|0 vOE@irEdK t1!PLm rZ t-KtR$t H9X-+FM9v2M -FixFb%)I`b)-- XKy^LGeK?_e aA&?em&3 o)!!RR!!6 t~NttN~ ?)Q8 XS2CX0 KKKKddDd= q&]&,u!}~3X rb bk ~R$m~(&{~R( 3MTx ,b-EJ!EZf-fJ.

For an exhaustive list of BGB-11417 monotherapy and combination clinical trials, view the jx/xLA#6x!J o*7/*s@.


  1. Hu, N. FQ Ci. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. ?%Pmmf z@Q 2020;80:3077.
  2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. 05N. Mcr. m,e7 c2TXgi 2017;16: 273–284.
  3. Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? /|AA G5lxl V\ppX` 2018;25:56–64.


Please login or register for full access


Already registered?  Login

Chat with BeiGene